- Home
- STTK vs AADI Comparison
STTK vs AADI Comparison
Compare STTK & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- AADI
- Stock Information
- Founded
- STTK 2016
- AADI 2011
- Country
- STTK United States
- AADI United States
- Employees
- STTK N/A
- AADI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- AADI Health Care
- Exchange
- STTK Nasdaq
- AADI Nasdaq
- Market Cap
- STTK 56.8M
- AADI 77.5M
- IPO Year
- STTK 2020
- AADI N/A
- Fundamental
- Price
- STTK $1.23
- AADI $2.73
- Analyst Decision
- STTK Hold
- AADI Hold
- Analyst Count
- STTK 3
- AADI 3
- Target Price
- STTK $2.00
- AADI $1.75
- AVG Volume (30 Days)
- STTK 127.4K
- AADI 256.8K
- Earning Date
- STTK 02-27-2025
- AADI 03-12-2025
- Dividend Yield
- STTK N/A
- AADI N/A
- EPS Growth
- STTK N/A
- AADI N/A
- EPS
- STTK N/A
- AADI N/A
- Revenue
- STTK $6,435,000.00
- AADI $25,070,000.00
- Revenue This Year
- STTK $313.04
- AADI $8.43
- Revenue Next Year
- STTK N/A
- AADI $5.41
- P/E Ratio
- STTK N/A
- AADI N/A
- Revenue Growth
- STTK 382.75
- AADI 7.80
- 52 Week Low
- STTK $0.94
- AADI $1.21
- 52 Week High
- STTK $11.76
- AADI $3.81
- Technical
- Relative Strength Index (RSI)
- STTK 52.10
- AADI 42.92
- Support Level
- STTK $1.11
- AADI $2.85
- Resistance Level
- STTK $1.36
- AADI $2.98
- Average True Range (ATR)
- STTK 0.11
- AADI 0.15
- MACD
- STTK 0.01
- AADI -0.07
- Stochastic Oscillator
- STTK 56.67
- AADI 11.24
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.